Hormesis has been defined as a dose-response relationship in which there is a stimulatory response at low doses, but an inhibitory response at high doses, resulting in a U-or inverted U-shaped dose response. To assess the proportion of studies satisfying criteria for evidence of hormesis, a database was created from published toxicological literature using rigorous a priori entry and evaluative criteria. This study, which provides the first documentation of a dataderived frequency of hormetic responses in the toxicologically oriented literature, indicates that when the study design satisfies a priori criteria (i.e., a well-defined NOAEL, > 2 doses below the NOAEL, and the end point measured has the capacity to display either stimulatory or inhibitory responses), hormesis is frequently encountered and is broadly represented according to agent, model, and end point. These findings have broad-based implications for study design, risk assessment methods, and the establishment of optimal drug doses and suggest important evolutionarily adaptive strategies for dose-response relationships.
The occurrence of hormesis in the toxicological sciences has a long and controversial history (Calabrese and Baldwin, 2000a,b,c,d,e) . Evidence supporting the existence of hormesis is substantial, with numerous reproducible examples suggesting potential broad generalizability (Calabrese et al., 1999) . However, little information exists concerning the frequency of hormesis within the toxicological literature; that is, how often one would expect to observe hormesis given appropriate study design parameters. Two databases were previously created from the published literature to quantify aspects of hormetic responses in toxicological studies. In the case of Davis and Svendsgaard (1994) , an attempt was made to estimate the incidence of hormetic responses based on the frequency of deviation from control responses independent of study design, NOAEL (no observed adverse effect level), and statistical significance. The second database (Calabrese and Baldwin, 1997a,b) focused on describing the quantitative features of the hormetic dose response and issues relating to generalizability rather than frequency in the toxicological literature.
Taking into consideration the limitations of the previous databases and incorporating suggestions by Crump (2001) , a new database was created to assess the proportion of studies in the toxicological literature satisfying criteria for evidence of hormesis consistent with the definition of Stebbing (1998) . Rigorous a priori entry criteria were established based on study design characteristics to identify data sets with the potential to detect a hormetic effect. Data sets meeting these criteria, independent of outcome, were entered into the database. Subsequent application of a priori evaluative criteria identified those dose-response relationships satisfying requirements for evidence of hormesis.
greater opportunity to address issues of generalizability. Furthermore, inclusion of approximately 30 years of articles from each journal ensured the opportunity to incorporate independent peer review over prolonged periods, studies reflecting changes in toxicological funding priorities (thereby enhancing the range of chemicals, end points, and hypotheses assessed), improvements in study design, analysis, and technical developments as the field evolved, and assessment of historical trends if needed.
Screening protocol. All articles were initially screened in ascending chronological order beginning with volume 1, number 1 of each journal through 1998, with the exception of Life Sciences. Due to the increasingly large number of articles published per year in this journal (by the end of 1979 approximately 6000 articles had been screened with an annual publication rate increasing to over 600 articles), a decision was made to limit additional screening to 6 years, approximately equally spaced over the remaining 19 years of publication (1982, 1985, 1988, 1992, 1995, 1998) . During the initial screening, exclusion and entry criteria described below were applied to all dose-response relationships reported in tabular or graphical form in each article. Dose-response relationships meeting the entry criteria were later examined with evaluative criteria described below for satisfying or not satisfying evidence of hormesis. The initial screening and the subsequent application of evaluative criteria were performed by the two authors; the results of the application of evaluative criteria were examined a second time by one of the authors.
Exclusion criteria.
Only studies with experimental data were considered. Review articles, abstracts, non-English language articles, epidemiologic studies, and field studies were excluded. Studies lacking any of the following conditions were excluded: (1) a concurrent control; (2) the capacity to achieve responses greater than (or less than, depending on end point) the control response (e.g., studies where the end point was survival and the control response was 100% or where the end point was tumor incidence and the control response was zero); (3) at least two doses below the NOAEL; and (4) at least one dose showing a priori criteria-based inhibition.
2 NOAEL designation. The NOAEL designation represents a unique dose that can be satisfied by only one dose. In the hormesis database this dose is satisfied by definitional determinants such that this dose represents the highest dose not differing from the control and having defined decrements at immediately higher doses. Any dose lower than this designated NOAEL that displays a response below that of the control would be interpreted as displaying either variability or error. As a result of this definition of NOAEL and applying it consistently throughout the database, possible subjective reinterpretation and designation of the NOAEL dose was prevented. The implications of this scheme were to allow for the inclusion of negative variability/error in the dose-response relationship below a designated NOAEL to permit false-positive estimation. If this approach had not been followed, some dose-response relationships could have been eliminated from satisfying entry criteria, ultimately resulting in a higher proportion of studies satisfying the evaluative criteria.
Residual bias may occur as a result of the NOAEL designation used in this assessment. Some doses that are characterized as NOAELs may in fact display evidence of low/modest toxic responses. However, if the decrement does not achieve a certain designated level (e.g., statistical significance, percent decrement), a determination could be made for that dose being the NOAEL. Thus, it is possible to inappropriately designate a bona fide LOAEL (lowest observed adverse effect level) as a NOAEL. This concern is widely recognized in regulatory toxicology and is one of the reasons why the NOAEL has been broadly criticized with respect to its no adverse effect designation. This possible limitation has led to proposals for application of statistical procedures, such as the benchmark dose (BMD), to estimate the NOAEL. If a NOAEL is actually a LOAEL in the current hormesis database, this would have implications for detection of hormesis at lower doses in the dose response spectrum. In fact, it could limit the potential detection to possibly one dose under certain study design scenarios. Again, even this one dose may still actually represent a type of LOAEL, if in fact it too had low residual deficits. This suggests that for dose responses in the present hormesis database where the NOAEL reflects a dose with a slight/modest toxic response, a false-negative potential for hormesis estimation may exist.
A decision was made in the development of the criteria to include as NOAELs for evaluative purposes doses that could satisfy evaluative criteria for evidence of hormesis. Although it is possible that one could have eliminated NOAELs within an evaluative designation, this approach was rejected, since the NOAEL, when it exceeds the control value, could be considered as being in the hormetic zone. This is because the designation of the NOAEL is not a perfect representation of the zero equivalent point (i.e., the highest dose with a response equal to the control response), but could err on either side of the control for real biological effect purposes. For this reason, it was decided that it would be unfair to bias a determination against a hormetic perspective. It should be noted that it was argued above that mischaracterization of a LOAEL with a NOAEL could lead to false-negative representation. However, allowing a NOAEL to be positively identified as a hormetic response is not a misrepresentation.
Entry criteria. The entry criteria were designed to ensure consistency with the U (or inverted U) shape of the hormetic dose-response relationship. That is, all studies needed to have sufficient evidence to demonstrate the occurrence of high-dose inhibition based on statistical and/or quantitative criteria, a NOAEL, and doses below the NOAEL that were to be evaluated for the potential of a low-dose stimulatory response based on statistical and/or quantitative criteria. Studies satisfying these general criteria were placed into one of three entry criteria tiers (T1, T2, T3) presented in Table 1 : T1 includes dose-response relationships subjected to hypothesis testing; T2 was designed to identify dose-response relationships lacking hypothesis testing but reporting standard deviation (SD) or standard error of the mean (SEM) information, thereby providing information on the distribution of the data. T3 was designed to identify dose-response relationships defined only by data points reflecting mean/median values with no reference to variation.
Evaluative criteria. All dose-response relationships meeting the entry criteria were then subjected to evaluative criteria for evidence of hormesis (Table 1 ). An outcome satisfying criteria for evidence of hormesis is considered indicative of a dose-response relationship demonstrating stimulation at low doses and inhibition at higher doses. (See Fig. 1 for examples of data sets satisfying evaluative criteria.)
Where no hypothesis testing was performed, a difference of at least two SD or two SEM between the control and treatment group was considered indicative of potential statistical significance. Although our intent was to standardize all such data to conform to a similar distribution (i.e., SEM), this was not possible because of considerable variability in the nature and specificity of the information provided (e.g., out of a total of 196 dose-response relationships in category T2, 66 distributions were reported as SEM, 60 were reported as SD, and 70 were not identified). Consequently, we used the distribution provided in the paper, recognizing that the comparison between studies would lack the intended uniform comparability.
In cases where data were graphically represented, on some occasions error bars were depicted for treatment data points, but not for the control. In those cases the dose responses were considered indicative of potential statistical significance if the error bars (SD/SEM ϫ 2) of the treatment did not cross the control value.
In order to avoid exclusion of potentially relevant data below the NOAEL and to enhance the rigor of evaluative criteria, dose-response relationships with at least three doses with responses Ն 110% of control (or with responses Յ 90% for J-or U-shaped curves), i.e., alternative quantitative criteria were considered satisfying evidence of low-dose stimulation in the absence of statistical significance or potential statistical significance as determined by data distribution.
In order to avoid exclusion of potentially relevant data due to absence of a statistically significant or potentially statistically significant inhibitory response at high doses, dose-response relationships with at least two doses with responses Ͻ 90% of control (or Ͼ 110% for J-or U-shaped curves) were considered satisfying evidence of inhibition in the absence of statistical significance or potential statistical significance as determined by data distribution.
Assessment of false-positive responses. An indication of the frequency of false-positive responses (i.e., to what extent the positive findings could be accounted for by chance or random variation) was obtained by assessing the responses of treatment doses below the NOAEL and comparing the proportion of negative findings to positive findings. This is based on the assumption that if chance or random variation was responsible for the positive findings (i.e., a hormesis designation) then the number of negative responses should approximate the number of positive responses. It should be noted that although the NOAEL dose was included when assessing dose-response relationships with the evaluative criteria (Table 1) , only treatment doses below the NOAEL were evaluated for false-positive responses. The NOAEL by definition cannot display an adverse (or negative) response, and its inclusion in the assessment of false-positives would therefore bias the outcome. By excluding the NOAEL values in this assessment, bias favoring false-positive estimation was minimized. This approach therefore provides a rate of false-positive/negative estimates that could be applied to the total rather than deriving the absolute number by direct estimation.
When the evaluative criteria were based on the response of single doses, the proportion of false-positive findings was derived by dividing the total number of doses below the NOAEL showing significant or potentially significant negative responses by the total number of significant or potentially significant responses of a positive and negative nature for both the hypothesis testing (T1) and distributional data (T2) categories. A similar procedure was employed to estimate false-positive findings when alternative quantitative criteria were used.
Assessment of false-negative responses. An indication of the frequency of false-negative responses was obtained by assessing the proportion of doseresponse relationships satisfying the alternative quantitative evaluative criteria to the total number of dose-response relationships not satisfying evaluative criteria in the hypothesis testing category T1. This procedure was also applied Note. T1, dose-response relationships subjected to hypothesis testing; T2, designed to identify dose-response relationships lacking hypothesis testing but reporting SD or SEM, thus providing data distribution information; T3, designed to identify dose-response relationships defined only by data points reflecting mean/median values with no reference to variation.
a NOAEL, no observed adverse effect level. For the purposes of this study the NOAEL was defined as the highest dose with a response not statistically significantly different from the control with respect to adverse effects in studies where hypothesis testing was performed; in studies lacking hypothesis testing and in studies where hypothesis testing was performed but statistical significance was not observed with respect to adverse effects, the NOAEL was defined as the highest dose with a response Ն 90% of the control for inverted U-shaped dose-response relationships or as the highest dose with a response Յ 110% of the control for U-or J-shaped dose-response relationships.
b For the purposes of this study inhibition must be demonstrated as follows: at least one dose higher than the NOAEL with a response statistically significantly different from the control in studies where hypothesis testing was performed; at least one dose higher than the NOAEL with a response showing no 2 times SD/SEM overlap with the control in studies where data distribution was reported; or at least 2 doses higher than the NOAEL with responses Ͻ 90% of the control.
c Please note that these descriptions apply to inverted U-shaped dose-response relationships; in the case of J-(or U-) shaped dose-response relationships the evaluative response criterion value including and/or below the NOAEL is Յ 90% of control and the evaluative response criterion above the NOAEL is Ͼ 110% of control.
d Consistent with the U-(or inverted U-) shape of the hormetic dose-response relationship.
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RESULTS

Frequency of Hormetic Effects
Assessment of False-Positive Responses
Tables 4 and 5 present the results of the assessment of false-positive responses for each entry/evaluative criteria category. The collective findings indicate that the false-positive rate from the various categories was approximately 4%. When the false-positive/negative values were totaled, it yielded a net 1.4% false-positive estimate. This would reduce the 36.7% hormesis frequency to 35.3% (Table 6 ). These findings indicate that the methodology was not very susceptible to false-positive/negative error.
Assessment of False-Negative Responses
There were 139 dose-response relationships in T1 that satisfied entry but failed to satisfy evaluative criteria for hormesis. Thirteen of these 139 dose-response relationships satisfied the alternative quantitative evaluative criteria. This value provides an estimate of the false-negative rate for hormesis of 9.3% within the hypothesis testing criteria (category T1, Fig. 2) . A similar procedure applied to the distributional data revealed a false-negative rate of 10.1% (category T2, Fig. 2) . A direct comparison of dose-response relationships satisfying evaluative criteria for both hypothesis testing and alternative quantitative criteria revealed that such dose responses were approximately twice as likely to satisfy the evaluative criteria for hypothesis testing than for alternative criteria (i.e., of the 75 dose-response relationships satisfying hypothesis testing criteria, 38 also satisfied alternative criteria). That is, it is twice as difficult to have three doses at and/or below the NOAEL with responses Ն 110% of the control response as to have one of these doses with a responses statistically significantly greater than the control. These findings not only strongly support the use of the methodology to estimate false-negative rates, but also indicate that the actual false-negative rates are likely to be higher than estimated. These results also suggest that the findings provided in the alternative criteria for hormetic estimates are considerably more rigorous than the hypothesis testing and distributional methods.
DISCUSSION
The findings indicate that in studies satisfying entry criteria, 36.7% satisfied the evaluative criteria for a hormetic response. Although the above assessment indicates that the study findings cannot be accounted for by false-positive responses or by Note. % ϭ no. satisfying evaluative criteria/ no. satisfying entry criteria. Metabolic endpoints include enzyme activities, photosynthesis rate, respiration rate, protein synthesis, etc. Physiologic endpoints include muscle contraction/ relaxation, blood pressure, heart rate, etc. Pesticides include insecticides, herbicides, fungicides and ectoparasiticides. Miscellaneous includes a variety of agents and mixtures (e.g., pharmaceutical products, receptor agonists and antagonists, detergents, etc.).
FIG. 2.
Summary of application of the evaluative criteria to the 668 dose-response relationships satisfying the entry criteria, organized by category. See Table 1 for category descriptions. random variation, there are fundamental limitations in the current study methodology that are likely to yield a tendency for false-negative conclusions (values lower than actual hormesis estimates). The false-negative rate was nearly three times greater than the false-positive rate (i.e., 9.7% vs 3.5%). The false-negative criteria were established as being twice as rigorous as the false-positive estimation procedure. Finally, while false-positive evaluation was able to be applied to all possible instances for positive responses, this was not the case for the 170 negative dose responses in the alternative quantitative criteria for which no validation procedure is available. Given these three factors, it is likely that the 36.7% estimate of hormetic dose-response frequency is conservative and is likely somewhat higher.
In addition, the study did not take temporal factors into consideration. Numerous investigations exist that demonstrate stimulatory responses occur only following a disruption in homeostasis, that is, after an initial decrement in response (Stebbing, 1998; Calabrese, 2001) . If responses were not taken at multiple times during the experiment, possible stimulatory responses could be missed, leading to false-negative conclusions.
It is interesting to note that of 1089 treatment doses below the NOAEL using hypothesis testing and distributional data entry criteria (Table 4) , 213 (19.5%) of the treatment doses were determined to satisfy hormesis evaluative criteria. Only seven treatment doses (7/1089 ϭ 0.6%) were significantly below the control. This suggests that hormetic responses in these categories occurred approximately 30-fold (19.5%/0.6% ϭ 32.5) more frequently than a response of similar magnitude in the opposite (negative) direction. This finding, which employs the treatment doses below the NOAEL as the unit of comparison, provides striking support for the position that hormetic effects cannot be attributed to chance.
The data further revealed that the general occurrence for hormetic dose responses was widely incorporating of biological model, end points, and chemical classes. These findings represent the first attempt to assess the frequency of hormetic responses within the context of a biological/toxicological model based on study design, dose response, and statistical features. The results are particularly noteworthy, as they directly challenge the long-held view that hormetic responses should be seen as statistical exceptions, paradoxical findings, or otherwise unexpected events. Note. The values of 110% and 90% refer to inverted U-shaped dose-response relationships; the values would be reversed in the case of U-(or J-) shaped dose-response relationships. Positive hormesis evidence, total number of dose-responses with at least 3 doses below the NOAEL with a response Ն 110%. Chance positive evidence, total number of dose-responses with at least 3 doses below the NOAEL with a response Յ 90%. False positive rate, false positive/positive ϩ false positive. Although the above findings suggest that hormetic responses are quite common if assessed with the appropriate study design criteria, only 1% of the more than 20,000 published articles contained data meeting the study design criteria for entry into the database. This emphasizes the fact that very few published studies have the potential for detecting hormetic responses in the low-dose region of dose-response relationships. In fact, the criteria used in the present study ignored temporal features. If adequate temporal features were required, the proportion of studies satisfying entry criteria would have been far less than the 1%. Yet, if hormetic effects are to be adequately characterized, multiple appropriately spaced doses need to be assessed over multiple periods. The dual combination of multiple doses and periods places extraordinary demands on the investigation and are generally ignored, at least in part, thereby affecting the opportunity to assess hormetic effects. Thus, it is not surprising that hormetic effects have been considered exceptions or paradoxical responses, as our findings indicate that only 1 of 100 studies has the appropriate dosage design needed to assess this hypothesis.
Although there are multiple reasons why entry criteria were not satisfied, the most likely reason is that the hormetic evaluation has high study design criteria requirements, especially with respect to the number of doses and doses below the NOAEL. At a minimum, four doses plus a concurrent control are required, with two of the four doses being below the NOAEL. Historically, there has been a strong emphasis on high-dose evaluation, as these responses are often more definitive and publishable for defining the NOAEL. These factors minimize the proportion of experiments that emphasize below-NOAEL responses. Likewise, there has been the long-standing belief that responses below the NOAEL are most likely due to normal variation and not reproducible treatment effects. It is this very central assumption of modern experimental and regulatory toxicology that the present findings challenge. Yet, it is this historically controlling assumption that has strongly influenced past toxicological study designs and contributes to the observation that 99% of studies do not satisfy the entry criteria for hormetic responses.
The selection of the three journals noted in the Methods section was designed to achieve a broad representation of biological models, agents tested, and end points assessed. Although this approach was generally successful in achieving these goals, there were several important omissions or underrepresentations in certain categories. For example, the number of microbiological models was minimally represented; likewise, studies involving various types of radiation were also minimal. Nonetheless, areas such as microbiological responses and effects of radioactivity have been extensively documented and are represented in the earlier and separate database developed by Calabrese and Baldwin (1997a,b) . Such underrepresentation in the present study is believed to be a result of the journal selection rather than a biological restriction of the hormetic response.
The findings presented here add to and strengthen the earlier reports on the potential widespread generalizability of hormesis. They provide a useful complement to the Calabrese and Baldwin (1997a,b) hormesis database, which includes several thousand examples of dose-response relationships satisfying quantitative criteria for assessing hormesis, as well as study replication and mechanistic findings that account for the biphasic nature of the dose and temporal responses of the hormetic phenomenon. Although numerous examples of apparent hormetic responses exist independent of chemical, biological model, and end point, the previous database cannot address the issue of frequency of occurrence of hormetic responses. The current study addresses this limitation and suggests that hormetic responses are commonly encountered if the study design is appropriate.
The present findings have important implications for the a This is based on the assumption that these categories adjust for false negative responses by employing alternative quantitative evaluative criteria in cases where the data do not satisfy statistical significance (T1) or potential statistical significance as indicated by data distribution (T2). The estimated potential false negative responses are 9.3% (13/139) for dose-response relationships satisfying hypothesis testing entry criteria and 10.1% (14/139) for dose-response relationships satisfying distributional data entry criteria.
design, conduct and interpretation of toxicological investigations as well as the potential to alter current concepts of NOAEL and challenge findings of risk assessment modeling activities commonly used for regulatory practices that assume linearity in low-dose areas. More specifically, for hormetic effects to be properly assessed, it is important that consideration be given to animal model and end-point selection. For example, an assessment of end points such as mutagenicity, carcinogenicity, and teratogenicity within a hormetic framework cannot be made using models with zero or negligible background/control incidence. It is also important to establish in a reliable manner the NOAEL for end points of interest and to include multiple and carefully spaced doses below the NOAEL. Furthermore, it may be necessary to include a temporal component within the study design if the hormetic mechanism represents an overcompensation response (Hart and Frame, 1996; Morré, 2000; Stebbing, 1998) . The above suggestions are not trivial recommendations, as they require the commitment of substantial additional resources. Nonetheless, these features are necessary to more properly determine the nature of the dose response in the low-dose zone.
These findings address fundamental aspects of the nature of the dose response in the low-dose zone and suggest the need to incorporate U-shaped features in future modeling aspects of biological responses. Although the current investigation has focused on toxicologically derived data, sufficient data exist within the original hormesis database to indicate that this phenomenon is operational and similarly significant across the broad spectrum of biological, pharmacological, and other biomedical disciplines.
